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1. Introduction
Various drugs are being introduced into market for generating beneficial therapeutic effects
in humans. The pharmaceutical industry invests about $1.5 billion over the time period of 10-15
years to take a candidate drug from primary screen to market. Unfortunately, many drugs are
withdrawn due to side effects associated with off-and on-target toxicity [1]. For example, as
many as nine out of ten promising candidates beginning clinical phase I will not achieve
marketing approval [2] and only 20% of agents that show efficacy against cardiovascular
diseases in preclinical development are licensed after demonstrating sufficient efficacy in
phase III testing [3]. The success rate in anticancer drug development process is with 5% of
licensed agents even lower. Off-target cardiac toxicity is the most common cause of regulatory
delay in approval and market withdrawal of newly developed pharmaceuticals [4, 5]. Drug-
induced sudden cardiac death and ventricular arrhythmia caused the withdrawal of more
drugs in recent years than any other adverse drug reaction. Moreover, over 100 non-cardiac
drugs are suspected to be of high-risk and carry cardiovascular-related black box warnings [6].
Similar considerations are raised concerning arrhythmia and toxicity induced by environ‐
mental factors, including industrial chemicals, food additives, cosmetics, and others, as
outlined in the European REACH initiative (Registration, Evaluation, Authorization and
Restriction of Chemical substances).
Current drug safety evaluation processes that are required for regulatory purposes mostly rely
on animal studies and immortalized cell-based assays due to lack of suitable human in vitro
cell systems. In Europe, almost 10 million vertebrate animals are used annually for research.
Although highly predictive assays involving whole heart or slice preparations and in vivo
animal testing remain the standard for preclinical safety pharmacology, this extensive use of
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animals and their tissues does not eliminate high attrition rates of novel drugs. One of the
major reasons for this is limited predictability of existing preclinical animal (and cellular)
models for assessment of drug safety and efficacy. Animal models do not always predict the
toxicity in humans with sufficient accuracy because of inter-species differences [7]. For
example, murine and human hearts greatly differ in some aspects of electrophysiological
properties [8]. In addition, inbred animals that are frequently used in these analyses do not
mimic the genetic diversity of human population required for accurate prediction of drug
responses [9]. Therefore, identification of reliable and robust human cell systems for toxicity
assessment has become a driving interest for pharmaceutical industries.
In cardiac area different types of tests are already playing an important role in reducing costs
and drug attrition rates. These strategies involve a tiered system which starts with in vitro
single cell analyses followed by tests with ex vivo tissues and organs and progresses to in vivo
animal models and, finally, clinical trials [10]. The most important in vitro test consists of
automated patch-clamp recordings of Chinese hamster ovary (CHO) cells expressing human
Ether-à-go-go-Related Gene (hERG) channel. This test is being used to identify compounds
that block hERG channel and prolong cardiac action potential (AP) duration (i.e. the QT
interval) predisposing to Torsade de pointes tachycardia and sudden cardiac death [11]. The
assessment of the torsadogenic potential of each compound in the drug discovery process also
includes determination of drug’s ability to prolong the AP in isolated, arterially perfused rabbit
ventricular wedge preparations or canine Purkinje fibers and monitoring of heart rates and
occurrence of arrhythmia in animals. Each of these endpoints has it’s own specificity and
sensitivity [12]. For example, hERG-expressing CHO cells lack the complexity of native CMs
and cannot accurately predict the organ toxicity or lethal and arrhythmogenic side effects of
compounds that block other channels or signaling pathways. Therefore, additional in vitro
assays that better recapitulate human pathophysiology and diversity are needed to better
predict all potential on-and off-target toxicities, reduce drug attrition rates and avoid use of
animals for testing drugs that would never reach clinical application.
Pluripotent stem cells (PSCs) have unrestricted proliferation capacity, are able to differentiate
into any differentiated cell type thus offering a cost-effective unlimited and invaluable source
of organotypic differentiated cells relevant to assess human long-term organ toxicity. The
ethical issues associated with human embryonic stem cells (ESCs) were a major concern in
their application in toxicity studies. However, the Nobel prize-winning discovery that
transient expression of a few transcription factors can stably convert an adult somatic cell into
an early embryonic stage, i.e. into so called induced pluripotent stem cells (iPSCs) [13], has
opened new possibilities in drug discovery circumventing ethical issues and problematic
accessibility.
Repeated dose toxicity (RDT) occurs after repeated exposure to a substance over certain period
of time. In the context of cosmetics, which are generally used for months and years, long-term
RDT testing is of particular importance and forms the integral part of the quantitative risk
assessment. The prediction of endpoints and hazard identification of both newly developed
and existing cosmetic ingredients in humans is mainly based on the animal systems as they
allow simultaneous evaluation of multiple organ systems. However, there is a great demand
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and need for the development of multidisciplinary integrated approaches consisting of human
in vitro models for risk assessment as an alternative to animal models as they better mimic the
human in vivo system [14].
In this chapter, we will summarize the latest developments in applications of PSCs and their
tissue-specific derivatives for toxicity testing. We will outline the recent developments in
toxicogenomic technologies which are employed to develop and investigate human biomark‐
ers for toxicity in PSC based models accelerating drug development process. We mainly focus
on the application of PSCs in RDT testing.
2. Human pluripotent stem cells for repeated dose toxicity assessment
Human pluripotent stem cells (PSC) offer with their ability to recapitulate the most essential
steps of embryonic development and give rise to different mature cell types in vitro an optimal
human cellular model, which could help in increasing the safety and predictability of RDT
testing leading to low late stage attrition of compounds. Combined with this cell model,
toxicogenomic technologies would help predict biomarkers in an evidence-based approach.
So far, the safety assessment for novel drug candidates includes in vivo RDT tests in rodent
and non-rodent models. The drawbacks of RDT studies include false negative results and
unexpected humans toxicity of compounds that were judged to be safe in preclinical studies
[15, 16]. Such unexpected toxicity is one of the major reasons for the withdrawal of a drug from
the market. The heart and liver are often target organs in toxicology. Novel in vitro screening
methods are, thus, required to classify toxic compounds earlier in development, which would
lead to safer drugs, more efficient drug discovery process, lower costs and reduced laboratory
animal use [17]. There is an increasing interest from biopharmaceutical industry to develop
such test systems by using derivatives of human ESCs or iPSCs.
The iPSCs have a clear advantage over ESCs as they do not involve ethical issues. The
generation of iPSCs involves reorganization of condensed chromatin to open state chromatin,
which is aided by histone acetylation. Epigenetic factors are crucial for iPSC generation and
maintenance of their pluripotent state. Although the epigenetic state of iPSCs largely resembles
that of ESCs, iPSCs also have a unique DNA methylation patterns they retain epigenetic
memory of the respective somatic tissue of origin which might influence their differentiation
potential and affect the quality and quantity of cells for RDT [18]. On the other side, it is also
well known that different agents, so called epimutagens, can cause DNA methylation and
histone modification changes leading to disease [19]. These epigenetic modifications directly
affect transcription factors and other chromatin binding proteins that regulate cell type-specific
gene expression. The detection of biomarkers related to epigenetic modifications in RDT would
be of great importance, but until now there are no systematic studies conducted in this
direction. In addition, employing of iPSCs and their derivatives for this purpose poses a great
challenge because genetic and epigenetic variations in iPSCs associated with reprogramming
and in vitro manipulation may compromise their utility for downstream applications [20]. The
lesser the variation in epigenetic changes in iPSCs the greater will be the specificity in in vitro
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toxicological studies. Recently, Planello and coworkers demonstrated that the choice of
reprogramming factors greatly influences the DNA methylation abnormalities in iPSCs. Even
highly selected iPSC lines have been shown to retain epigenetic signature of donor cell [21].
Gupta et al have shown that global transcriptional profiles of human iPSCs and ESCs are very
similar and that this similarity also exists between the corresponding beating clusters derived
from them [22]. They have also shown that some fibroblasts-specific mRNA expression
partners were retained in the iPSCs derived from them. Significant proportion of these genes
were also shown to be expressed at the same level in iPSC-derived but not in ESC-derived
beating clusters indicating the retention of epigenetic memory even in the differentiated and
highly enriched iPSC derivatives. Likewise, several microRNA expression profiling studies
have shown the subtle differences between iPSC derivatives [23]. Hence, the iPSCs may not
represent an ideal platform for RDT testing. With the current pace of iPSC research it may be
possible to create iPSCs with little or no epigenetic anomalies. Polo and coworkers have shown
that this retained epigenetic memory of iPSCs in early passages can be erased using extensive
continued passage [24]. By using chromatin-modifying compounds like HDAC inhibitors it
may be possible to stabilize the epigenetic state of iPSCs and their derivatives and decrease
the frequency of heterogeneity within iPSCs. However, using the PSC-derivatives to predict
RDT in human toxicological endpoints is still challenging.
3. PSC-derived cardiomyocytes for toxicity testing
Human Stringent cosmetics legislation amending directives especially within the European
Union (EU) related to complete replacement of animal models in cosmetic industry safety
testing by alternative methods has emphasized an urgent need for the development of
reduction, refinement and replacement (3R) of the existing animal studies [25]. In order to fill
gaps in non-animal alternative methods and to focus on complex RDT a research initiative
called "Safety Evaluation Ultimately Replacing Animal Testing 1 (SEURAT-1)" composed of
six complimentary research projects was launched in 2011 and jointly funded by the European
Commission’s FP7 HEALTH Programme and Cosmetics Europe (http://www.seurat-1.eu/).
Embryonic Stem cell-based Novel Alternative Testing Strategies (ESNATS) is a European
Union's Seventh Framework Programme (FP7), which focuses on developing a human ESC
based novel toxicity test platforms to accelerate drug development. Human ESC based in vitro
reproductive toxicity, neurotoxicity, toxicogenomics, proteomics and kinetics were tested for
their predictive value in the identification of toxicity endpoints (http://www.esnats.eu). The
RDT delivers the No Observable Adverse Effect (NOAEL), which is used in calculation of the
substance safety parameters [25]. PSC-derived models hold a great potential for refinement of
current models of cardiotoxicity. For many toxicology applications, a homogeneous defined
population of specific cell types is required which stem cells can provide.
Validity of human PSC-derived cardiomyocytes (CM) for toxicity testing and safety pharma‐
cology has been investigated in several studies [26-28]. The susceptibility of disease-specific
human iPSC-CMs to toxicity compared to healthy human PSC-CMs was evaluated recently
by Joseph Wu laboratory [29]. This group showed that disease-specific human iPSC-CM are
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more accurate predictors of drug-induced cardiotoxicity than standard hERG-expressing
HEK293 cells. This observation suggests that human iPSC-CM may represent a suitable model
for evaluation of drug safety and efficacy. However, there is still a need to examine how well
the alternative systems can replace the animal models for RDT testing. The traditional
repeated-dose toxicological endpoints that relate to cardiotoxicity include histopathological
examinations of the heart and electrocardiographic recordings in the non-rodent species [30].
The current regulatory framework guidelines for cardiotoxicity testing include blood pressure,
heart rate and electrocardiogram (ECG) parameters as well as repolarization and conductance
abnormalities, cardiac output, ventricular contractility and vascular resistance. The limitations
of RDT testing in vivo clearly encouraged the scientific community to identify and develop
alternative in vitro methodologies to thoroughly estimate the integrated and complex re‐
sponses in the endpoints that are taken into consideration.
Drugs exerting toxic effects on cardiovascular system have shown to affect the heart function
in a way that includes changes in the contractility, cardiac rhythm, blood pressure and ischemia
[31]. Such toxic effects have led these drugs to be withdrawn, requiring expansion of rules on
cardiotoxicity testing. A new application for CMs derived from human ESCs and iPSCs has
surfaced because of the lack of availability of human primary material for cardiotoxicity testing
and their ability to overcome species variability. In vitro cardiotoxicity testing applications
using human PSC-CMs is very advantageous and complimentary to the existing RDT appli‐
cations. Endpoints such as action potential parameters, metabolic activity, membrane leakage,
energy content and intracellular calcium handling can be monitored for assessing cardiotox‐
icity. As mentioned above, the effect of new drugs on cardiac electrophysiology (i.e. changes
in ventricular repolarization) is a focus for tight control. The balanced concerted activity of
several cardiac ion channels is important for proper ventricular repolarization and alterations
may lead to ventricular arrhythmias. Therefore, electrophysiological assessment of the
proarrhythmic potential of drugs is very relevant in cardiotoxicity assays and human PSC-
derived CMs are suitable for such assays because they exhibit calcium handling properties,
ion channel activity and regulatory protein expression important for the development of a
mature repolarization phenotype in CMs [12].
Recently, several studies evaluated the potential of human iPSC-CMs for pharmacological
screening-assays and drug discovery applications [32-34]. However, the utility of iPSC-CMs
to accurately predict toxicity in humans may be limited by their immature character [35].
Current differentiation protocols give rise to heterogeneous phenotypes of spontaneously
beating human PSC-CMs with structural proteins, Ca2+release units, ion channels, action
potentials, and hormonal response being similar to that of native fetal CMs. However, the
electrophysiological and structural properties of PSC-CMs do not fully resemble those of adult
CMs. Therefore, the model based on human PSC-CMs must be improved before it can
represent an ideal platform for cardiac RDT. The mentioned issues can be solved by following
measures: a) by modulating cellular signaling pathways it is possible to get a homogeneous
CM population [36] b) with the application of tissue engineering it is possible to create a 3D
tissue constructs which provide microenvironment similar to native heart thus helping in
structural maturation of CMs [37] and c) prolonged culturing of iPSC-CMs can increase the
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maturation of Ca2+handling [38]. Further improvements of differentiation methods will enable
generation of more homogeneous and mature CM populations thus increasing their validity
for RDT testing. The overall predictability of drug efficacy and toxicity using iPSC-CMs and
disease specific iPSC-CMs has been recently reported by several groups [29, 39-41]. An absolute
requirement for CMs to be used for RDT is to be able to stably maintain the beating cardiac
phenotype for a prolonged period of time under defined conditions. Both hiPSC-CMs and
hESC-CMs display beat rate variability similar to that of a human heart sinoatrial node [42].
However, recently, variability in action potentials and sodium currents in response to lidocaine
and tetrodotoxin was shown in late stage in vitro differentiated human iPSC-CMs [32], thus
warranting some caution and further analyses.
Bioanalytics is a very promising tool in the application of in vitro cardiotoxicty assays. Novel
bioanalytical tools for discovery of biomarkers of cardiotoxicity include the field potential QT
scanning, using cellular oxygen uptake for monitoring the metabolic state of CMs, using
surface plasmon resonance (SPR) biosensing for key CM biomarkers, and also exploiting real-
time multi-wavelength fluorimetry [12]. Novel imaging technologies and physiological
analyses such as impedance measurements [43] and microelectrode arrays (MEAs) [44] give
an insight into major in vitro cellular events such as migration, proliferation, cell morphology,
cell–cell interactions and colony formation, relevant to biomarker discovery.
4. Stem cell-derived hepatocytes for toxicity testing
So far, hepatotoxicity is evaluated on day 28 or 90 in in vivo RDT tests by analysis of clinical
parameters, hematology, and histopathology. RDT tests evaluate chronic effects on organ
toxicity to establish a NOAEL which is used in calculation of the substance safety parameters
[25]. The extrapolation of the quantitative risk assessment for cosmetic ingredients using data
derived from animal studies to in vitro systems could be done by considering a margin of
safety (MoS) value of at least 100 for intra-species and inter-species variation [25]. Human PSCs
represent a promising human cellular model which could help in increasing the safety and
predictability of RDT testing. Combined with this cell model, toxicogenomic technologies
would help predict biomarkers in an evidence-based approach. During these RDT tests, the
animals are observed for indications of toxicity. Afterwards, necropsy, blood analysis and
histopathology of the organs of the animals are performed [17]. However, these parameters
can turn out to be insensitive and potentially generate false negative results [15, 16]. Unex‐
pected hepatotoxicity may be seen in the clinical trials or even when the product is already on
the market because careful examinations of idiosyncratic (person specific) or non-idiosyncratic
inter-drug interactions are either ignored or overseen [45]. This is also probably because of
dose-dependent reactions and other unknown peculiar drug interactions. There is need for
novel screening methods that can address these hepato-toxicological hazards early in the
development [46]. Most studies relied on the use of liver slices as an in vitro model for toxicity
testing due to limited availability of tissue samples. However, the human PSC-derived
hepatocytes have the potential to replace these in vitro models and be applied for toxicity
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assessment. The suitability of hepatocyte-like cells derived from human PSCs for toxicity
testing and drug discovery were systematically studied by several groups [47-49].
5. Omics strategies to develop biomarkers for RDT
5.1. Toxicogenomics
Proteomics, genomics and metabonomics, either alone or in combination have the potential
for developing biomarkers in applied toxicology. Toxicogenomics refers to the areas men‐
tioned above and is a thorough-mean for hi-throughput discovery of biomarkers using latest
technologies [50]. Transcriptomics measures the levels of both coding and non-coding RNAs
using hi-throughput technology such as microarrays. This whole genome gene expression
analysis can measure the levels of expression of a gene at any stage, in any tissue and in any
vitro model. Examples of toxicogenomics applications include prediction of genotoxicity or
carcinogenicity, target organ toxicity and endocrine disruption. Expression profiling of any
selected cellular systems exposed to new test substances is compared against controls to
identify, classify and validate toxic compound and its effects. Bioinformatic analyses of the
data sets obtained from above can be used to predict the patterns and signatures of a toxin
(e.g. biological processes or signaling pathways affected by a toxin). Furthermore, the data sets
can be matched up against existing databases for predicting and carving out a mode-of-action
for the toxin. The main disadvantage of this approach is limited reproducibility and also it is
semi quantitative and detects only changes in gene expression. Therefore, mRNA expression
profiling cannot be used as a standalone method in identifying potential biomarkers of RDT.
EU FP7 project Predict-IV is evaluating the integration of ‘omics’ technologies, biomarkers and
high content imaging for the early prediction of toxicity of pharmaceuticals in vitro. The aim
is to identify general molecular response pathways that result from toxic drug effects that are
independent of the cell/tissue type [51]. Detection of endpoints and biomarkers of RDT using
in vitro systems (DETECTIVE) is a unique large scale SEURAT-1 cluster project aimed at
establishing screening pipeline of high content, high throughput as well as classical functional
and “-omics” technologies to detect human biomarkers for RDT in in vitro test system (http://
www.detect-iv-e.eu/). Other-omics technologies such as microRNA analysis and epigenetics
also play a vital role.
5.2. Proteomics
Drug induced toxicity can also exhibit various effects at the proteome level. Classification of
such endpoints is difficult using traditional RDT methods. Proteomics improves the classifi‐
cation by identifying individual proteins or such protein panels that reflect the specific toxic
pathway mechanisms. Proteomics-based in vitro toxicity assays measure drug-induced
changes by comparing in vitro to in vivo effects thus validating the suitability of in vitro
models. There is an absolute need for integration of standard RDT tests with the ‘omics’
applications. Current proteomic technologies include gel-based (1-DE or 2-DE) and gel-free
(LC-MS/MS) techniques [17]. Recently thalidomide-specific proteomics signatures during
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human ESCs differentiation were identified using two-dimensional electrophoresis coupled
with Tandem Mass spectrometry [52]. Proteomic studies are quantitative, sensitive and are
more accurate and powerful in detecting protein biomarkers of RDT. Main pitfalls include
posttranslational changes and limited protein detection capacity.
5.3. Metabonomics
Human PSCs offer a potential alternative test system for the identification of developmen‐
tal toxicants [53]. Metabonomics refers to profiling of diverse metabolic complement of a
biofluid  or  tissue  using  analytical  tools  such  as  high-field  NMR  together  with  mass
spectrometry [54]. Subsequent statistical modeling and analysis of a multivariate spectral
profiles obtained using NMR [55] in combination with LC-MS and UPLC helps to distin‐
guish the phenotypes and metabolites of interest. These metabolites might represent new
biomarkers for toxicity. Previously, some of metabolites were identified to be biomarkers
for a variety of pathological diseases [56]. Metabonomics-based approaches have proved to
be  highly  successful  in  furthering  our  understanding  of  research  in  the  field  of  drug
metabolism, drug pathways and toxicology [54, 55]. In addition, metabonomics provides a
useful  link between ‘omics'  platforms such as genomics,  transcriptomics and proteomics
and end-stage histopathological analyses [54].
The Consortium for Metabonomic Toxicology (COMET) project (a collaboration between five
pharmaceutical companies and Imperial College London) focused on pre-clinical toxicological
research and resulted in the generation of an extensive 1H NMR biofluid spectral database
which was used for screening of toxins and also to build an expert system for prediction of
target organ toxicity [57]. A follow-up project, COMET-2, is currently investigating the detailed
biochemical mechanisms of toxicity, and seeks a better understanding of inter-subject variation
in metabonomics analyses [55]. Several groups have developed Metabonomics-based robust
human ESC in vitro test systems for predicting human developmental toxicity biomarkers and
pathways [58, 59]. Metabonomics is the most relevant and robust omics platform to study both
in vivo and in vitro toxicology. It is possible to detect metabolites with accuracy but it is limited
by its high costs and complex metabolite isolation procedures.
6. Bioinformatic and statistical analysis of candidate biomarkers
Since the omics methods are extensively data-intensive and bulk, there is a definite need for
bioinformatics and statistical analysis for organizing the data in conveniently accessible
databases, which integrate huge number of data sets, and therefore need quality database
manager software such as SQL for centralized storage and flexible web based access to the
bulk data.
Noncommercial databases available on the web such as CEBS (chemical effects in biological
systems, (http://cebs.niehs.nih.gov), PhenoGen (http://phenogen.uchsc.edu), along with and
commercial databases like ArrayTrack and ArrayExpress (http://www.ebi.ac.uk/arrayexpress)
help to generate large data sets. These are complemented by metabonomics databases (http://
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www.hmdb.ca). PrestOMIC is proteome-specific open-source that is a user-friendly database,
where researchers can upload and share data with the scientific community using a custom‐
izable browser [60]. Such a database helps researchers to increase the exposure and impact of
their data by enabling extensive data set comparisons.
Another open-source systems biology application called SysBio-OM, integrates information
from the CEBS database with other open source projects, including MAGE-OM (micro-array
gene expression object model) and PEDRo (proteomics experiment data repository), to model
profiling of protein, and metabolite expression and protein-protein interactions following
insult [61]. SysTox-OM is a more specific application that performs expression profiling of
genome, proteome, and metabolome, after the introduction of a toxicant. Different omics
approaches and some of the crucial data bases are summarized in Table.1. While incorporating
toxicological endpoints such as – clinical chemistry, hematology, observations and histopa‐
thology, it profiles the phenotype [62]. With this application, one can identify a single toxic
phenotype, classify, and compare gene and protein expression profiles in an organ after
administration of each drug. It is also possible to predict a common toxicologic pathway,
mechanism or a biomarker. ToxBank is an EU FP7 project aimed at establishing a dedicated
web-based warehouse for toxicity data management and modeling along with establishing a
cell and tissue banking information for in vitro toxicity testing.
Databases Web links
To
xic
og
en
om
ics
Comparative Toxicogenomics Database (CTD)
Open TG-GATEs
DrugMatrix®
TOXNET
ArrayExpress
diXa Data Warehouse
ArrayTrack™
http://ctdbase.org/
http://toxico.nibio.go.jp/english/
https://ntp.niehs.nih.gov/drugmatrix/index.html
http://toxnet.nlm.nih.gov/index.html
http://www.ebi.ac.uk/arrayexpress/
http://wwwdev.ebi.ac.uk/fg/dixa/index.html
http://www.fda.gov/ScienceResearch/
BioinformaticsTools/Arraytrack/default.htm
Pro
teo
mi
cs PRIDE
ProteomicsDB
GPMDB
NIST
http://www.ebi.ac.uk/pride/archive/
https://www.proteomicsdb.org/
http://gpmdb.thegpm.org/
http://peptide.nist.gov/
Me
tab
on
om
ics
Human Metabolome Database (HMDB)
BiGG
MetaboLights
MMCD
SetupX & BinBase
BML-NMR
MassBank
Golm Metabolome Database (GMD)
http://www.hmdb.ca/
http://bigg.ucsd.edu/
http://www.ebi.ac.uk/metabolights/index
http://fiehnlab.ucdavis.edu/projects/binbase_setupx
http://www.bml-nmr.org/
http://www.massbank.jp/
http://gmd.mpimp-golm.mpg.de/
Table 1. Summary of different Omics approaches and corresponding databases
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7. Conclusion and future perspective
Improved toxicity testing methods complementing advanced in vitro assays are very crucial
in reducing the rate of attrition in final stages of product development. To avoid failures and
withdrawals, there is an absolute need for integration of all available technologies to minimize
cumbersome process of trials and expenses and eventually reduce the increasing costs of
bringing a new drug into market. Supplementing toxicology evaluation methods, such as
histopathology, physiology and clinical chemistry with transcriptomics, proteomics and
metabonomics could provide new insights into the mechanisms underlying toxicological
pathologies. Integration of in vitro toxicology technologies, with systems biology methods
resulted in ‘systems toxicology’. Expansion of open source databases and analytical platforms
is critical to the discovery of novel biomarkers of toxicity. So far, the available approaches for
discovery of biomarkers included toxicogenomics, toxicoproteomics, metabonomics and
bioinformatics analyses (systems biology approach) while the technologies available for
quantification include ELISA, solid phase ELISA, Luminex technology and patterned paper
technology [50]. Individual technologies have limited usefulness unless the data generated
from these assay platforms and ‘-omics’ discovery technologies are integrated. The discovery
of DNA microarrays and protein chips has made information exchanges extraordinarily easy,
convenient and quick. Integration of information from these powerful sources using analytical
computing software products, noncommercial databases, and advances in hi-throughput
technology is the future of the next phase in the identification, selection and qualification of
novel biomarkers of toxicity.
Future of toxicogenomics lies in developing a more refined understanding of molecular
mechanisms related to specific toxicologies, to elucidate molecular signatures associated with
the prediction of biomarkers or panels of biomarkers with support from the field of transcrip‐
tomics, metabolomics, and proteomics. These analytical tools applied to the emerging human
PSC-based in vitro platforms utilizing their organ-specific differentiated derivatives, such as
CMs, hepatocytes and neurons, have a great potential to revolutionize the field of toxicology.
However, the full potential of these human in vitro cell-based platforms in predicting toxicity
of compounds in humans will be realized only with further improvements in derivation of
highly standardized, well-defined and homogeneous cell populations that functionally and
structurally strongly resemble their adult counterparts and development of sensitive and
robust methods for accurate detection of toxicity.
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